CCR7 and breast cancer: A meta-analysis of 30 studies investigating the role of CCR7 in solid tumors, including BC, revealed that a higher expression of CCR7 was associated with poorer overall survival (HR 1.79, 95% CI 1.49–2.16, p < 0.001) and progression-free survival (HR 2.18, 95% CI 1.49–3.18, p < 0.001).